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Abstract Arthritis is characterized by pain and functional
limitation affecting the patients’ quality of life. We per-
formed a clinical study to investigate the efficacy of a
betamethasone valerate medicated plaster (Betesil) in im-
proving pain and functional disability in patients with ar-
thritis and osteoarthritis. We enrolled 104 patients affected
by osteoarthritis (n = 40) or arthritis (n = 64) in different
joints. Patients received diclofenac sodium cream (2 g, four
times a day) or a 2.25-mg dose of Betesil applied to the
painful joint every night before bedtime for 10 days. Pain
and functional disability were assessed, by the Visual
Analogue Scale (VAS) and Western Ontario McMaster
Universities Osteoarthritis Index (WOMAC) scores.
Redness was assessed by clinical inspection, and edema
by the Bfovea sign^ method. C-reactive protein (CRP)
was also measured; CRP can be used to cost-effectively
monitor the pharmacological treatment efficacy and is
increased during the acute-phase response, returning to
physiological values after tissue recovery and functional
restoration. All measurements were at baseline and at
10-day follow-up. At 10-day follow-up, a greater improve-
ment in VAS and WOMAC pain and WOMAC stiffness
and functional limitation scores from baseline was observed
in patients treated with Betesil compared with diclofenac
(all p < 0.01). At 10-day follow-up, improvement in red-
ness, edema, and CRP levels from baseline was also greater
in patients treated with Betesil compared with diclofenac
(all p < 0.01). This study demonstrates the safety and effi-
cacy of transdermal delivery of betamethasone valerate in
patients affected by arthritis and osteoarthritis.
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Introduction
Arthritis is a pathological condition that causes pain and in-
flammation in a joint. Osteoarthritis (OA) is the most common
form of arthritis and is defined as a degenerative mesenchymal
disease affecting an estimated 10 % of the world’s population
over 60 years [1, 2]. Symptoms include pain, stiffness, and
functional limitation, leading to loss of autonomy and poor
quality of life [3]. Various treatment options are available for
OAmanagement. These include (1) non-steroidal anti-inflam-
matory drugs (NSAIDs) for pain management [4], (2)
bisphosphonates to decrease pain and improve functionality
by preserving the structural integrity of subchondral bone [5],
(3) pulsed electromagnetic field therapy [6], and (4)
viscosupplementation, with hyaluronic acid alone or in com-
bination with bisphosphonates or NSAIDs, to improve pain
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and functional activity [7–9]. Indeed, viscosupplementation
with hyaluronic acid improves articular cartilage degeneration
and decreases osteophyte formation, as shown by experimen-
tal studies using OA models [10, 11]. Topical corticosteroids
also decrease pain and improve joint functionality [12, 13].
The non-pharmacological management of OA includes edu-
cation and self-management, exercise and weight loss, assis-
tive devices, alternative and complementary approaches, and
surgical interventions [14].
Transdermal delivery of betamethasone valerate for treat-
ment of arthritis So far, only a few studies have investi-
gated the clinical efficacy of transdermal delivery of cor-
ticosteroids for OA management. Corticosteroids for the
treatment of arthritis may be administered by iontophore-
sis, a non-invasive technique that allows transdermal drug
delivery. Betamethasone valerate (BMV) is a synthetic,
moderately active corticosteroid without mineralocorti-
coid properties, [15] which binds the intracellular cyto-
plasmic glucocorticoid receptor and translocates it to the
nucleus to function as a ligand-activated transcription fac-
tor [16]. Eight sessions of dexamethasone iontophoresis
have been used for treatment of juvenile idiopathic arthri-
tis affecting the temporomandibular joint [17]. Resolution
of pain occurred in 73 % of the patients who had pain at
baseline. On the other hand, a second study, evaluating
the efficacy of a transdermal steroid delivery vs. placebo
by iontophoresis or phonophoresis for the treatment of
patients with trapeziometacarpal arthritis, did not show
significant differences between treatments [18].
The aim of this study was to compare the efficacy of trans-
dermal BMVand diclofenac sodium cream in patients affected
by arthritis and OA, in order to determine the best therapeutic
option in terms of pain, redness, edema, and functional
disability.
Materials and methods
This study was performed at the Poliambulatorio del Secondo
Parere clinic (Modena, Italy) in accordance with the
Declaration of Helsinki and approved by the Institutional
Review Board at Poliambulatorio del Secondo Parere
(Modena, Italy). All patients signed the informed consent
and agreed to data collection and review.
Patients’ demographics and disease characteristicsA total
of 104 patients (62 males and 42 females) participated in
this study. Originally, 106 patients were recruited but two
patients, affected by hip arthritis, dropped out soon after
recruitment due to the development of a symptomatic her-
niated disc and excluded from data analysis. Inclusion
criteria were symptomatic arthritis and OA with a Visual
Analogue Scale (VAS) pain score ≥ 60 mm. Exclusion
criteria were hypersensitivity or allergy to the active com-
ponent of the plaster, presence of skin edema, and joint
effusions. Patients had a mean age of 57.3 ± 1.09
[mean ± standard error of the mean (SEM)]. Patients were
diagnosed on the basis of medical examination and ortho-
pedic evaluation using ultrasound, radiography, and mag-
netic resonance imaging as follows: bilateral knee OA
(n = 24), hip arthritis (n = 4), OA with bulging disc be-
tween L4 and L5 (n = 16), sciatic nerve inflammation
deriving from spinal arthritis occurring at L4, L5, and
S1 (n = 20), shoulder arthritis (n = 28), and carpal tunnel
syndrome associated with arthritis affecting the wrist
(n = 12) (Table 1). All patients signed the informed
consent.
Study design Patients were matched on the basis of age, sex,
and type of pathology (p = 0.958, p = 0.318, and p = 0.84,
respectively; Table 1). Patients were instructed to apply a
2.250-mg BMV medicated plaster (Betesil; n = 52) on the
painful joint every night before bedtime for 10 days or
diclofenac sodium cream (n = 52; 2 g) on the painful joint
four times a day for 10 days. If pain relief was not adequate,
patients were instructed to take diclofenac sodium orally as
rescue medication (50 mg, up to three capsules per day).
Pain and functional disability assessmentVAS (0–100 mm;
0 mm = minimum pain; 100 mm = maximum pain) and
Western Ontario McMaster Universities Osteoarthritis Index
(WOMAC) scores were used to evaluate the efficacy of
Betesil on pain and functional disability at 10-day follow-up.
WOMAC is based on five items related to pain (subscore 0–
20; 0 = minimum pain; 20 = maximum pain), two to stiffness
(subscore 0–8; 0 = minimum stiffness; 8 = maximum stiff-
ness), and 17 to functional limitation (subscore 0–68; 0 = min-
imum functional limitation; 68 = maximum functional
limitation).
Redness and edema assessment Redness was assessed by
visual clinical inspection (subscore 0–3; 0 = absence of
redness, 1 = slight redness, 2 = moderate redness, and
3 = intense redness). Edema was assessed by the “fovea
sign” method [19]. The fovea sign is positive when there is
exquisite tenderness compared with the contralateral side
and is scored as follows: subscore 0–3, 0 = absence of
edema, 1 = 2-mm edema following depression of the skin,
2 = 4-mm edema following depression of the skin, and 3 =
5-mm edema following depression of the skin.
C-reactive protein The venous blood of all fasting sub-
jects was drawn in the morning, and C-reactive protein
(CRP) levels were detected by immunoturbidimetric
method, using an automated analyzer. CRP has been
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extensively used in the orthopedic and rheumatology
clinics [20, 21]. CRP is increased during the acute-
phase response while it returns to physiological values
following tissue recovery and functional restoration [22].
Therefore, in this study, CRP was used to allow cost-
effective monitoring of the pharmacological treatment
efficacy.
Statistical analysis Patients’ age is presented as
mean ± SEM; VAS, WOMAC, and CRP data are reported
as median [interquartile range (IQR)]; edema and
redness data are presented as frequencies (percentages)
(Table 1). Comparison of age between groups was per-
formed using Student’s t test. Comparison of post-
treatment percentage variation from baseline for VAS,
WOMAC, and CRP data was performed using
Wilcoxon’s signed-rank test. Comparison of post-
treatment percentage variation for edema and redness
data from baseline was performed using Pearson’s chi-
square test. A p value < 0.05 was considered signifi-
cant. All statistical analyses were conducted using R
software [23].
Table 1 Patients’ demographics
and disease characteristics at
baseline and 10-day follow-up
Diclofenac sodium cream (n = 52) Betesil (n = 52) p
Age 57.06 ± 1.52 57.54 ± 1.6 0.958
Female patients 18 (35 %) 24 (46 %) 0.318
Male patients 34 (65 %) 28 (54 %)
Arthritis (non-rheumatoid) 33 (63 %) 31 (60 %) 0.84
Osteoarthritis 19 (37 %) 21 (40 %)
Carpal tunnel syndrome/wrist arthritis 7 (13 %) 5 (10 %) 0.902
Hip arthritis 2 (4 %) 2 (4 %)
Knee osteoarthritis 10 (19 %) 14 (27 %)
Osteoarthritis with bulging disk (L4–L5) 9 (17 %) 7 (13 %)
Sciatic nerve inflammation/spinal arthritis 9 (17 %) 11 (21 %)
Shoulder arthritis 15 (29 %) 13 (25 %)
VAS (mm; baseline) 75 (70–80) 87 (78–91.25) < 0.01
VAS (mm; follow-up) 65 (60–70) 35 (32–43.25) < 0.01
WOMAC (pain; baseline) 14 (10–17) 15 (10–19) 0.384
WOMAC (pain; follow-up) 12 (9–16) 7 (4–10) < 0.01
WOMAC (functional limitation; baseline) 51.5 (40.75–60) 51 (39–61.25) 0.706
WOMAC (functional limitation; follow-up) 47 (38.5–55) 25.5 (17–39.25) < 0.01
WOMAC (stiffness; baseline) 5 (4–7) 6 (4.75–8) 0.083
WOMAC (stiffness; follow-up) 4.5 (3–6) 3 (2–4.25) < 0.01
CRP (mg/l; baseline) 4.25 (2.98–6.03) 4.75 (3–6) 0.848
CRP (mg/l; follow-up) 3.65 (2.1–5.73) 2.25 (1–3) < 0.01
Redness (baseline; score = 0) 0 (0 %) 0 (0 %) 0.32
Redness (baseline; score = 1) 9 (17 %) 15 (29 %)
Redness (baseline; score = 2) 19 (37 %) 14 (27 %)
Redness (baseline; score = 3) 24 (46 %) 23 (44 %)
Redness (follow-up; score = 0) 0 (0 %) 21 (40 %) < 0.01
Redness (follow-up; score = 1) 17 (33 %) 18 (35 %)
Redness (follow-up; score = 2) 15 (29 %) 13 (25 %)
Redness (follow-up; score = 3) 20 (38 %) 0 (0 %)
Edema (baseline; score = 0) 0 (0 %) 0 (0 %) 0.189
Edema (baseline; score = 1) 12 (23 %) 12 (23 %)
Edema (baseline; score = 2) 28 (54 %) 20 (38 %)
Edema (baseline; score = 3) 12 (23 %) 20 (38 %)
Edema (follow-up; score = 0) 0 (0 %) 23 (44 %) < 0.01
Edema (follow-up; score = 1) 20 (38 %) 23 (44 %)
Edema (follow-up; score = 2) 21 (40 %) 6 (12 %)
Edema (follow-up; score = 3) 11 (21 %) 0 (0 %)
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Results
Table 1 shows baseline and 10-day post-treatment patients’
characteristics. At 10-day follow-up, a greater reduction in
VAS (Fig. 1a) and WOMAC pain (Fig. 1b) scores from base-
line was observed in patients treated with Betesil (55.44 ±
1.28% and 52.4 ± 2.31%, respectively), when compared with
diclofenac sodium cream (13.89 ± 0.8 % and 12.35 ± 1.26 %,
respectively; all p < 0.01). A greater reduction in WOMAC
functional limitation (Fig. 1c) and stiffness (Fig. 1d) scores
from baseline was observed in patients treated with Betesil
(44.79 ± 2.33 % and 50.03 ± 3.08 %, respectively), when
compared with diclofenac sodium cream (9.62 ± 0.79 % and
14.94 ± 2.26%, respectively; all p < 0.01). A similar trend was
observed for redness (Fig. 2a) and edema (Fig. 2b) scores in
patients treated with Betesil, when compared with diclofenac
sodium cream (all p < 0.01). A greater reduction in CRP levels
(Fig. 3) from baseline was also observed in patients treated
with Betesil (46.54 ± 3.52 %), when compared with
diclofenac sodium cream (14.42 ± 1.25 %; p < 0.01). During
the study, diclofenac sodium was used by 15 patients; 10
patients took two capsules a day for 2 days and then a capsule
a day for 2 days during the first 4 days of plaster application. A
total of five patients took a capsule a day for 2 days, during the
first 2 days of plaster application. Only one patient reported a
skin rash 4 hours after the first application of the plaster. The
rash was thought to be an allergic reaction and resolved with-
out medication after 5 hours. This patient continued applying
the plaster the following days and completed the study.
Discussion
To the best of our knowledge, this is the first demonstration of
the clinical effectiveness and safety of a BMV medicated plas-
ter for treatment of symptomatic joint arthritis and OA.
Scientific interest in transdermal drug delivery systems has sig-
nificantly increased in the last two decades because this ap-
proach is considered a valid therapeutic alternative to oral and
more invasive strategies. The advantages of transdermal drug
delivery include better patient compliance, control over input
kinetics, and a lower incidence of gastrointestinal-related side
effects [24], as observed in this study. Furthermore, it avoids the
first-pass hepatic metabolism and plasma bioavailability
Fig. 1 Betesil improves arthritis and osteoarthritis pain. Percentage
variation in VAS pain (a), WOMAC pain (b), WOMAC functional
limitation (c), and WOMAC stiffness (d) scores from baseline at 10-day
follow-up following Betesil and diclofenac sodium cream treatment in
patients affected by arthritis and osteoarthritis affecting different joints
Drug Deliv. and Transl. Res.
fluctuations usually observed with oral administration [25]. In
conclusion, the present study shows that Betesil is well
tolerated and displays superior efficacy in reducing
pain and functional disability and ameliorating CRP
levels, redness, and edema, when compared with
diclofenac sodium cream, in patients affected by ar-
thritis and OA. The improvement in CRP levels sup-
ports tissue recovery and functional restoration [22]
allowing us to monitor the therapeutic efficacy of
Betesil and further supporting its use as a local phar-
macological therapy for arthritis pain and functional
disability.
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